

Company text



Galderma is a global leading pharmaceutical company specializing in the research, development and marketing of innovative medical solutions in dermatology.

Galderma is a joint venture between Nestlé and L'Oréal and today employs more than 3.000 people. The company, founded in 1981 and headed by President & CEO Humberto C. Antunes, has wholly-owned affiliates in 31 countries and a worldwide network of exclusive sales agents. In 2010, sales reached 1,2 billion euros, an increase of 16.1%* over 2009.

To drive sustained growth, Galderma invests approximately 20 percent of its revenues to discover and develop new drugs and access innovative technologies. Drugs and other medical solutions are sourced internally from Galderma's own research activities or from partnerships. The R&D teams are present on three sites:

- Princeton (NJ), USA (clinical development),
- Tokyo, Japan (clinical development),
- Sophia Antipolis, France (research and development). This 25.000-sq. meter state-of-the-art R&D center is Galderma's largest facility and positions the company as one of the world's leading investors in dermatology R&D.

Galderma also continually invests in leading-edge technologies and high-tech manufacturing facilities:

- The Alby-sur-Chéran plant in France was inaugurated in 1994 and produced 32.7 million units in 2010 to over 50 countries.
- The Baie d'Urfé (Montreal) plant in Canada started production in 2000 to meet the growing demand of the U.S. market where Galderma makes well over half of its global sales. The annual production was 55.8 million units in 2010.
- The Hortolândia site in Brazil (state of São Paulo) serves the regional markets.

Plant extensions are currently underway in France and Canada in order to optimize and boost production capacity. A three-year investment plan to ensure best-in-class standards for quality, safety and the environment.

With products sold in more than 70 countries and promoted by a sales force of around 1.000 representatives, Galderma provides a wide range of innovative medical solutions which meet the highest standards of safety and efficacy.

Beyond Differin, the company's historical home-grown product indicated for the topical treatment of acne, Galderma's growing portfolio includes several other major brands for treating rosacea, psoriasis and other steroid-responsive dermatoses (SRD), onychomycosis (fungal nail infections), pigmentary disorders, skin cancer and medical solutions for skin senescence.

The past few years have witnessed profound changes in the world of dermatology, with the introduction of new topical, systemic and biotech-based treatments, as well as new types of procedures being performed in dermatologists' practices. Galderma has therefore undertaken very promising, long-term partnership programs and acquisitions to reinforce its strategic development in the field of therapeutic, corrective and aesthetic dermatology.

Committed to the future of dermatology, Galderma's ambition is to be recognized as the most competent and successful innovation-based company focused exclusively on meeting the needs of dermatology patients and physicians.

* at comparable rates